{"id":"https://openalex.org/W2991165846","doi":null,"title":"Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study","display_name":"Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study","publication_year":2019,"publication_date":"2019-02-01","ids":{"openalex":"https://openalex.org/W2991165846","mag":"2991165846","pmid":"https://pubmed.ncbi.nlm.nih.gov/30811140"},"language":"en","primary_location":{"id":"pmid:30811140","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30811140","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Clinical Trial, Phase II"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080405405","display_name":"F Kerdel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Franz R. Kerdel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078045869","display_name":"Fabio A. Azevedo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fabio A. Azevedo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083699657","display_name":"Christina Kerdel Don","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christina Kerdel Don","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024745274","display_name":"Frank A. Don","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Frank A. Don","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026402548","display_name":"Gabriella Fabbrocini","orcid":"https://orcid.org/0000-0002-0064-1874","observed_orcids":["https://orcid.org/0000-0002-0064-1874"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gabriella Fabbrocini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5058395343","display_name":"Francisco A. Kerdel","orcid":"https://orcid.org/0000-0001-7242-8733","observed_orcids":["https://orcid.org/0000-0001-7242-8733"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Francisco A. Kerdel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":5.9743,"has_fulltext":false,"cited_by_count":37,"citation_normalized_percentile":{"value":0.96883337,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"18","issue":"2","first_page":"170","last_page":"176"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12328","display_name":"Autoimmune and Inflammatory Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13328","display_name":"Osteomyelitis and Bone Disorders Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hidradenitis-suppurativa","display_name":"hidradenitis suppurativa","score":0.9660000205039978},{"id":"https://openalex.org/keywords/apremilast","display_name":"apremilast","score":1.0},{"id":"https://openalex.org/keywords/phosphodiesterase-4-inhibitors","display_name":"phosphodiesterase-4 inhibitors","score":0.972000002861023},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.4869999885559082},{"id":"https://openalex.org/keywords/disease-activity","display_name":"disease activity","score":0.796999990940094},{"id":"https://openalex.org/keywords/pain","display_name":"pain","score":0.9179999828338623},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9950000047683716},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.875},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.7250000238418579},{"id":"https://openalex.org/keywords/depression","display_name":"depression","score":0.5640000104904175},{"id":"https://openalex.org/keywords/dermatology-life-quality-index","display_name":"Dermatology Life Quality Index","score":0.9010000228881836},{"id":"https://openalex.org/keywords/physician-s-global-assessment","display_name":"physician global assessment","score":0.8650000095367432},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.6019999980926514}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9694236516952515},{"id":"https://openalex.org/C2776002364","wikidata":"https://www.wikidata.org/wiki/Q341999","display_name":"Hidradenitis suppurativa","level":3,"score":0.9332555532455444},{"id":"https://openalex.org/C2781427535","wikidata":"https://www.wikidata.org/wiki/Q2858961","display_name":"Apremilast","level":4,"score":0.7581367492675781},{"id":"https://openalex.org/C14184104","wikidata":"https://www.wikidata.org/wiki/Q1362526","display_name":"Visual analogue scale","level":2,"score":0.6803843975067139},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6503050327301025},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.5419251918792725},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5099483728408813},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.5073050856590271},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3358141779899597},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000894","descriptor_name":"Anti-Inflammatory Agents, Non-Steroidal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000894","descriptor_name":"Anti-Inflammatory Agents, Non-Steroidal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005767","descriptor_name":"Gastrointestinal Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017497","descriptor_name":"Hidradenitis Suppurativa","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D017497","descriptor_name":"Hidradenitis Suppurativa","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058988","descriptor_name":"Phosphodiesterase 4 Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D058988","descriptor_name":"Phosphodiesterase 4 Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:30811140","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30811140","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Clinical Trial, Phase II"},{"id":"mag:2991165846","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30811140","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2811395800","https://openalex.org/W2615949569","https://openalex.org/W3212539010","https://openalex.org/W3192286512","https://openalex.org/W3082965565","https://openalex.org/W2901752465","https://openalex.org/W4405498530","https://openalex.org/W3003774838","https://openalex.org/W3160935870","https://openalex.org/W4390226253"],"abstract_inverted_index":{"Background:":[0],"Treatment":[1],"options":[2],"are":[3],"limited":[4],"for":[5,23,50,121,180],"patients":[6,24,80,144,160,170,265],"with":[7,25,41,81,266],"hidradenitis":[8],"suppurativa":[9],"(HS).":[10],"Apremilast,":[11],"an":[12,19],"oral":[13],"phosphodiesterase":[14],"4":[15],"inhibitor,":[16],"may":[17,274],"offer":[18],"attractive":[20],"therapeutic":[21],"option":[22],"mild-to-moderate":[26,42,267],"HS.":[27,43,268,285],"Methods:":[28],"This":[29],"open-label,":[30],"phase":[31],"2":[32],"clinical":[33],"trial":[34],"enrolled":[35,150],"adults":[36],"(\u226518":[37],"years":[38],"of":[39,79,159,169,282],"age)":[40],"Patients":[44],"received":[45],"apremilast":[46,273],"30mg":[47],"twice":[48],"daily":[49],"24":[51,109],"weeks":[52,162],"after":[53],"a":[54,82,276],"5-day":[55],"titration":[56],"period.":[57],"Therapy":[58],"was":[59,92,100,155,252],"discontinued":[60],"at":[61,89,161],"week":[62,69,90,108,184],"24;":[63],"data":[64,270],"were":[65,130,140,149,178,237,248],"collected":[66],"up":[67],"to":[68,107,193,203,214,225],"28.":[70],"Hidradenitis":[71],"Suppurativa":[72],"Clinical":[73],"Response":[74],"30":[75],"(HiSCR30),":[76],"ie,":[77,97],"proportion":[78,168],"\u226530%":[83],"reduction":[84],"in":[85,110,151,157,256,264,278],"abscesses":[86],"and":[87,123,164,219,234,254,262],"nodules":[88],"16,":[91],"the":[93,111,133,152,186,198,208,220,238,279],"primary":[94],"endpoint.":[95],"HiSCR50,":[96],"\u226550%":[98],"reduction,":[99],"also":[101],"explored.":[102],"Mean":[103],"changes":[104],"from":[105,176,191,201,212,223],"baseline":[106,177],"modified":[112],"Sartorius,":[113],"Physician\u2019s":[114],"Global":[115],"Assessment,":[116],"visual":[117],"analog":[118],"scale":[119],"(VAS)":[120],"pain,":[122,261],"Dermatology":[124],"Life":[125],"Quality":[126],"Index":[127],"(DLQI)":[128],"scores":[129],"analyzed":[131],"using":[132],"Wilcoxon":[134],"Rank-Sum":[135],"test.":[136],"Adverse":[137],"events":[138],"(AEs)":[139],"summarized.":[141],"Results:":[142],"Twenty":[143],"(mean":[145],"age,":[146],"32.5":[147],"years)":[148],"study.":[153],"HiSCR30":[154],"achieved":[156,171],"65%":[158],"16":[163],"24.":[165],"A":[166],"similar":[167],"HiSCR50.":[172],"Significant":[173],"mean":[174],"improvements":[175],"observed":[179],"all":[181],"assessments.":[182],"At":[183],"24,":[185],"overall":[187],"Sartorius":[188],"score":[189,200,211,222],"improved":[190],"35.6":[192],"13.9":[194],"(-21.7":[195],"change;":[196,206,217,228],"P<0.001),":[197],"PGA":[199],"2.7":[202],"1.6":[204],"(-1.1":[205],"P<0.01),":[207],"VAS":[209],"pain":[210],"27.6":[213],"10.9":[215],"(-16.8":[216],"P<0.05),":[218],"DLQI":[221],"11.6":[224],"5.4":[226],"(-6.2":[227],"P<0.01).":[229],"Diarrhea":[230],"(20%),":[231],"nausea":[232],"(15%),":[233],"depression":[235],"(10%)":[236],"most":[239],"commonly":[240],"reported":[241],"AEs.":[242],"No":[243],"serious":[244],"AEs":[245],"or":[246],"deaths":[247],"reported.":[249],"Conclusions:":[250],"Apremilast":[251],"safe":[253],"effective":[255],"improving":[257],"HS":[258],"disease":[259],"activity,":[260],"QoL":[263],"These":[269],"suggest":[271],"that":[272],"have":[275],"role":[277],"early":[280],"treatment":[281],"less":[283],"severe":[284],"J":[286],"Drugs":[287],"Dermatol.":[288],"2019;18(2):170-176.":[289]},"counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-12-05T00:00:00"}